Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
World game at war: why some European nations have threatened a World Cup boycott 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Michael Stocum to Step Down as Inivata CEO
Search for new CEO is underway
Research Triangle Park, NC and Cambridge, UK, May 8, 2018 -- Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care announces that Michael Stocum has stepped down as CEO to pursue other interests.
Michael Stocum said, "It has been a privilege leading Inivata as we grew from an academic spinout to our current stage of development over the past four years. The company is now entering its next stage of growth with an increasing focus on commercialisation and needs a CEO with a different set of skills."
Jeff Buchalter, Chairman, said, "I would like to thank Mike for his significant contribution to Inivata and wish him well in his future endeavours. Inivata has developed a highly-sensitive liquid biopsy platform that positions it strongly in a fast-growing market. I look forward to the next phase of the Company's development with considerable confidence."
The Company has initiated a search for a new CEO.
About Inivata
Inivata is a global clinical cancer genomics company utilizing a proprietary, industry-leading liquid biopsy platform to transform patient care. Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment. The InVision® liquid biopsy platform is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, combines industry-leading sensitivity with select multi-gene panels to provide clinically actionable information to clinicians. Inivata has established collaborations with world-leading cancer centers and academic institutions, and is partnering with pharmaceutical and biotechnology companies. The Company has a CLIA lab in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.
Media Contacts:
Consilium Strategic Communications
Chris Gardner/Laura Thornton
[email protected] +44 (0)20 3709 5700
Karen Chandler-Smith
[email protected] +44 (0)7900 430235
